arrow
M

Michela Roberto

department of hematology
H指数:25
被引数:1,786

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis

前列腺特异性抗原谷值对转移性激素敏感性前列腺癌预后的影响:一项系统评价和重建的个体患者数据荟萃分析

2026-08-070
OA
Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: Long-term Results of a Prospective Phase II Study
2025-01-010
OAAI
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

晚期肾细胞癌 (ARON-1) 患者对一线免疫联合药物的真实世界原发性耐药

2024-09-171
PRE
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments

创新肿瘤治疗癌症患者药物相互作用的临床意义

2024-08-010
PRE
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
2023-12-0121
OAAI
The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives
2023-06-014
PRE
The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
2023-01-124
OAAI
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

CDK4/6抑制剂Ribociclib在局部晚期和寡转移性激素受体阳性,Her2阴性,晚期乳腺癌中的作用: 病例系列和文献复习

2022-02-092
OAAI
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life, Case-Control Study

在左侧RAS和BRAF野生型转移性结直肠癌患者中,临床医生对双联加抗EGFR与三联加贝伐单抗作为一线治疗的态度: 一项多中心,现实生活,病例对照研究

2021-12-017
PRE
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
2021-10-275
OAAI